Yahoo Finance Evotec Full Year 2023 Earnings: EPS Misses Expectations
Evotec (ETR:EVT) Full Year 2023 Results
Key Financial Results
Revenue: €781.4m (up 4.0% from FY 2022).
Net loss: €83.9m (loss narrowed by 52% from FY 2022).
€0.47 loss per share (improved from €0.99 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Evotec EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 55%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Germany.
The company's shares are down 27% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Evotec that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
